AWAustin D. Williams

Austin D. Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Austin D. Williams has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Richard J. Bleicher

    Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA

    15 shared publications
  • Allison A. Aggon

    Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA

    9 shared publications
  • Andrea S. Porpiglia

    Division of Breast Surgery, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA

    7 shared publications
  • Cecilia Chang

    Research Institute, Endeavor Health, Evanston, USA

    7 shared publications
  • Walker Lyons

    Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA

    6 shared publications
  • Alycia So

    Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center, Philadelphia, USA

    5 shared publications

Latest Publications

  • Open Access

    National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer

    by Dylan S. Brokaw, Leonardo Kozian, Cecilia Chang, Rebecca M. Shulman, Richard J. Bleicher, Alycia So, Allison A. Aggon, Austin D. Williams

    Purpose: De-escalation has become standard across breast cancer management. Many early-stage HR+/HER2-negative breast cancers are eligible for both SLNB omission and accelerated partial breast irradiation (APBI). However, the oncologic safety of dual de-escalation has not been evaluated except in patients ≥ 70 years. We sought to characterize national practice patterns and factors associated with adoption of this dual de-escalation approach. Methods: Women aged 50–69 years with clinical T1–T2N0 breast cancer who underwent upfront breast-conserving surgery between (2012 − 2022) were identified from the National Cancer Database. Patients were categorized by axillary surgery and by adjuvant radiation modality (WBI, APBI, or none). We assessed trends and factors associated with de-escalation. Results: 316,324 patients met inclusion criteria, of whom 98% underwent SLNB. Among patients who underwent SLNB, 83% received WBI, 11% received APBI, and 6% received no radiation. In contrast, among patients in whom SLNB was omitted, 63% received WBI, 8% received APBI, and 30% received no radiation. SLNB omission remained low throughout the study period at < 3%, while APBI use increased from 8% to 16.5%. Dual de-escalation was rarely performed throughout the study period remaining < 0.30%. Shared predictors of de-escalation included cT1 tumors, ductal histology, low grade, and treatment at academic/research programs. Conclusion: These findings highlight the need for prospective studies to define the safety, outcomes, and patient selection criteria for combined de-escalation strategies. Until these data are available, patient-centered discussions are essential to determine the most appropriate strategy for patients with low-risk disease.

  • Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection

    by Austin D. Williams, Anna Weiss

    Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high‐risk, early‐stage disease. Cyclin‐dependent kinase 4 and 6 inhibitors, initially established as a standard component of first‐line therapy in the metastatic setting based on improvements in progression‐free and overall survival, have since been evaluated in the adjuvant setting. While adjuvant palbociclib did not improve invasive disease‐free survival, the monarchE and NATALEE trials demonstrated that abemaciclib and ribociclib, respectively, reduce recurrence risk in patients with high‐risk, early‐stage disease, with emerging overall survival data further supporting their use. However, the absolute magnitude of benefit varies substantially with baseline risk, and treatment‐related toxicity and adherence challenges must be considered, as approximately 20% to 25% of patients discontinue therapy before completion. The integration of these agents into clinical practice also intersects with ongoing efforts to deescalate axillary surgery, as treatment eligibility has been largely defined by anatomic staging, particularly nodal status. Available data suggest that the incremental impact of axillary surgery on identifying candidates for cyclin‐dependent kinase 4 and 6 inhibition is modest, especially among the favorable‐risk populations now eligible for surgical deescalation. As the field evolves, advances in molecular risk stratification, genomic profiling, and dynamic biomarkers are poised to shift treatment selection from anatomic staging toward biologically driven approaches. Multidisciplinary decision‐making that integrates tumor biology, anticipated absolute benefit, toxicity, patient preferences, and surgical considerations will be essential to ensure individualized care.

  • ASO Visual Abstract: Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria

    by Austin D. Williams, Walker Lyons, Lindsey B. Taylor, Cecilia Chang, Angela Jain, Melissa McShane, Allison A. Aggon, Alycia So, Jennifer Winn, Richard J. Bleicher

  • Open Access

    Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria

    by Austin D. Williams, Walker Lyons, Lindsey B. Taylor, Cecilia Chang, Angela Jain, Melissa McShane, Allison A. Aggon, Alycia So, Jennifer Winn, Richard J. Bleicher

    Introduction: Recent trials have expanded eligibility for omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer, while adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in patients with high-risk features that often rely on pathologic nodal status. The impact of SLNB omission on identifying candidates for CDK4/6 inhibitor therapy remains unclear. We evaluated how omission affects eligibility under Choosing Wisely and American Society of Clinical Oncology (ASCO) criteria. Methods: From the National Cancer Database (2018–2022), we identified women aged ≥ 50 years with hormone-receptor-positive, HER2-negative, clinical T1–2N0M0 breast cancer treated with upfront surgery and SLNB. Omission-eligible cohorts were defined based on Choosing Wisely and ASCO criteria. CDK4/6 inhibitor (abemaciclib and ribociclib) eligibility was assessed using tumor features alone (modeling omission), SLNB findings, and axillary lymph node dissection (ALND) findings. Multivariable logistic regression identified predictors of SLNB determining eligibility. Results: Among 150,629 patients, 73% met SLNB omission criteria. Positive SLNs were found in 9–10%, and only 2% had pN2–3 disease. SLNB omission would miss 4% (abemaciclib) and 8% (ribociclib) of eligible patients in the Choosing Wisely cohort, and 1 and 8%, respectively, in the ASCO cohort. ALND increased candidacy by only 1%. Approximately 13 SLNBs were required to identify one CDK4/6-eligible patient, and 299 SLNBs were required to identify one patient expected to derive a 5-year invasive disease-free survival benefit. Conclusions: SLNB omission excludes few patients eligible for adjuvant CDK4/6 inhibitor therapy. These findings support shared decision-making and suggest SLNB should not be performed solely to determine CDK4/6 eligibility.


  • Open Access

    Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection

    by Mahtab Vasigh, Karen Ruth, Richard J. Bleicher, Walker Lyons, Allison A. Aggon, Austin D. Williams

    Purpose: The role of axillary surgery in patients with de novo metastatic breast cancer (dnMBC) undergoing primary site surgery is unclear. We evaluated patterns of axillary management and associations with overall survival (OS) in this population. Methods: We used the National Cancer Database (2012-2020) to identify patients with dnMBC. Patients were grouped by receipt of breast surgery and axillary surgery (none, sentinel lymph node biopsy [SLNB] or axillary lymph node dissection [ALND]). Multivariable Cox proportional hazards models assessed factors associated with axillary surgery and OS. Results: Among 39,946 eligible patients, 7,808 (19.5%) underwent surgery of the primary site, of whom 79.8% underwent axillary surgery (79.5% ALND, 20.4% SLNB). Compared with no axillary surgery, those who underwent axillary surgery had more favorable clinicodemographic characteristics (younger, fewer comorbidities, lower T stage, bone-only metastases). In patients with clinically node-negative disease, 41.6% had pathologically negative nodes, with higher rates among those with HR+/HER- disease and those who did not have systemic therapy prior to surgery. On multivariable analysis, axillary surgery was independently associated with improved OS (HR 0.70; 95% CI 0.63–0.78; p<0.001). Conclusion: Among patients with dnMBC undergoing primary site surgery, axillary surgery was associated with improved survival in this retrospective analysis, though the effect is likely influenced by selection bias. Until prospective data define which subgroups may benefit, axillary surgery should be considered selectively, with SLNB preferred over ALND for patients without palpable adenopathy to minimize morbidity. Multidisciplinary evaluation remains essential to tailor surgical decisions that balance survival, function, and quality of life.

  • Open Access

    ASO Visual Abstract: Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes

    by Elizabeth M. Fish, Ian Whittall, Walker Lyons, Richard J. Bleicher, Rebecca M. Shulman, Cecilia Chang, Alycia L. So, Andrea S. Porpiglia, Allison A. Aggon, Austin D. Williams

  • Open Access

    Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes

    by Elizabeth M. Fish, Ian Whittall, Walker Lyons, Richard J. Bleicher, Rebecca M. Shulman, Cecilia Chang, Alycia L. So, Andrea S. Porpiglia, Allison A. Aggon, Austin D. Williams

    Background: Men are often diagnosed with node-positive breast cancer and treated with mastectomy because of a lack of screening and an unfavorable tumor-to-breast ratio. The AMAROS trial showed no difference in outcomes between axillary lymph node dissection (ALND) and axillary radiation in women with cT1-2N0 breast cancer with positive sentinel lymph nodes (+SLNs). Axillary management in men remains unstandardized, so we assessed current trends and outcomes. Methods: Males with cT1-2N0M0 breast cancer undergoing mastectomy with one to two +SLNs were identified from the National Cancer Database (2018–2021). Patients were stratified by axillary management. Postmastectomy radiotherapy (PMRT) included chest wall and axillary fields. Management strategies and overall survival were analyzed. Results: Among 445 patients, 25% had no further axillary treatment, 22% underwent ALND, 29% PMRT, and 24% ALND+PMRT. Patients with two +SLNs more often underwent ALND+PMRT (43% vs. 19%, p < 0.001). The use of PMRT rose over time (23–36%), whereas ALND alone declined (27–12%). Additional positive nodes were found in 31% of ALND cases, with no difference between ALND and ALND+PMRT. Performance of ALND delayed PMRT (194 vs. 133 days from diagnosis, p < 0.001). On multivariable analysis, two +SLNs predicted ALND+PMRT (odds ratio 2.5, p = 0.006). Older age ( p < 0.001) and two +SLNs ( p = 0.03) were linked to worse overall survival, whereas axillary management was not ( p = 0.23). Conclusion: Although axillary strategies are proven safe and effective in women, their extrapolation to men is inconsistent. Half of men undergoing mastectomy are undertreated or overtreated, underscoring the need for multidisciplinary consensus and prospective male-specific data to guide care and reduce morbidity.


  • Open Access

    Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy

    by Brenton Halsey, Elizabeth McAuley Fish, Walker Lyons, Melissa McShane, Austin D. Williams

    Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy